Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC811007 in type 2 diabetes mellitus with heart failure
ACTRN12612000739819Phase 2Completed
- Sponsor
- Protemix
- Start
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of trientine in type 2 diabetes mellitus (T2DM) and heart failure (HF) (3 arms), sponsored by Protemix. Primary endpoint: Change in time to reach 70% of peak oxygen consumption. Started Jul 2004; status: completed.
02
Drugs
trientine
03
Conditions
type 2 diabetes mellitus (T2DM)heart failure (HF)
Beyond the preview
Go deeper on ACTRN12612000739819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000739819.